Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Oligonucleotide-based therapies are advanced novel interventions used in the management
of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease …

Antisense technology is beginning to deliver on the broad promise of the technology. Ten
RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double …

Acromegaly is characterized by increased release of growth hormone and, consequently,
insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to …

Human growth hormone (GH) is a classical pituitary endocrine hormone that is essential for
normal postnatal growth and has pleiotropic effects across multiple physiological systems …

When coined, the term “antisense” included oligonucleotides of any structure, with any
chemical modification and designed to work through any post-RNA hybridization …

The delay in controlling the disease in patients who do not respond to first-line treatment
with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified …

Pituitary adenomas are benign tumours comprising approximately 16% of all primary cranial
neoplasms. Functioning pituitary adenomas (prolactinomas, somatotroph, corticotroph …

Background Whereas biochemical response is often used as a primary study outcome,
improvement in symptoms and health-related quality of life (HRQoL) is the relevant goal for …

Acromegaly is a rare disease with prevalence of approximately 60 cases per million, slight
female predominance and peak onset in adults in the fourth decade. Clinical diagnosis is …